Learning and memory after neonatal exposure to 3,4- methylenedioxymethamphetamine (ecstasy) in rats: Interaction with exposure in adulthood

Synapse

Volumn 57, Issue 3, 2005, Pages 148-159

  Cohen, Martha A ^a   Skelton, Matthew R ^a   Schaefer, Tori L ^a   Gudelsky, Gary A ^b   Vorhees, Charles V ^a,c   Williams, Michael T ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

^c CINCINNATI CHILDREN S HOSPITAL RESEARCH FOUNDATION   (United States)

Author keywords

Amphetamines; Development; Dopamine; MDMA; Preclinical; Serotonin; Spatial learning

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; DOPAMINE; SEROTONIN;

ADOLESCENT; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY TEMPERATURE; CINCINNATI WATER MAZE; CONTROLLED STUDY; CORPUS STRIATUM; FETUS; HIPPOCAMPUS; LEARNING; LOCOMOTION; MALE; MAZE TEST; MEMORY; MORRIS WATER MAZE; NEWBORN; NONHUMAN; NOVEL OBJECT RECOGNITION; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; TASK PERFORMANCE;

AGE FACTORS; ANALYSIS OF VARIANCE; ANIMALS; ANIMALS, NEWBORN; BEHAVIOR, ANIMAL; BIOGENIC MONOAMINES; BODY TEMPERATURE; BRAIN; BRAIN CHEMISTRY; ESCAPE REACTION; EXPLORATORY BEHAVIOR; HALLUCINOGENS; LEARNING; MALE; MAZE LEARNING; MOTOR ACTIVITY; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; ORGAN SIZE; RATS; RATS, SPRAGUE-DAWLEY; REACTION TIME; SPATIAL BEHAVIOR; STATISTICS; TIME FACTORS;

EID: 22544443904     PISSN: 08874476     EISSN: None     Source Type: Journal    
DOI: 10.1002/syn.20166     Document Type: Article

References (52)

1. Bayer SA, Altman J, Russo RJ, Zhang X. 1993. Timetables of neurogenesis in the human brain based on experimentally determined patterns in the rat. Neurotoxicology 14:83-144.
2. Broening HW, Bowyer JF, Slikker W Jr. 1995. Age-dependent sensitivity of rats to the long-term effects of the serotonergic neurotoxicant (+/-)-3,4-methylenedioxymethamphetamine (MDMA) correlates with the magnitude of the MDMA-induced thermal response. J Pharmacol Exp Ther 275:325-333.
3. Broening HW, Morford LL, Inman-Wood SL, Fukumura M, Vorhees CV. 2001. 3,4-Methylenedioxymethamphetamine (Ecstasy)-induced learning and memory impairments depend on the age of exposure during early development. J Neurosci 21:3228-3235.
4. Bull EJ, Hutson PH, Fone KCF. 2004. Decreased social behaviour following 3,4-methylenedioxymethamphetamine (MDMA) is accompanied by changes in 5-HT2A receptor responsivity. Neuropharmacology 46:202-210.
5. Clark RE, Zola SM, Squire LR, 2000. Impaired recognition memory in rats after damage to the hippocampus. J Neurosci 20:8853-8860.
6. Cole JC, Sumnall HR. 2003. The pre-clinical behavioural pharmacology of 3,4-methylenedioxymethamphetamine (MDMA). Neurosci Biobehav Rev 27:199-217.
7. Cole JC, Sumnall HR, O'Shea E, Marsden CA. 2003. Effects of MDMA exposure on the conditioned place preference produced by other drugs of abuse. Psychopharmacology 166:383-390.
8. Dafters RI, Hoshi R, Talbot AC. 2004. Contribution of cannabis and MDMA ("ecstasy") to cognitive changes in long-term polydrug users. Psychopharmacology 173:405-410.
9. Durstewitz D, Seamans JK, Sejnowski TJ. 2004. Dopamine-mediated stabilization of delay-period activity in a network model of prefrontal cortex. J Neurophysiol 83:1733-1750.
10. Ennaceur A, Meliani K. 1992. A new one-trial test for neurobiological studies of memory in rats. III. Spatial vs. non-spatial working memory. Behav Brain Res 51:83-92.
11. Fischer C, Hatzidimitriou G, Wlos J, Katz J, Ricaurte G. 1995. Reorganization of ascending 5-HT axon projections in animals previously exposed to the recreational drug (+/-)3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy"). J Neurosci 15:5476-5485.
12. Gallagher M, Burwell R, Burchinal M. 1993. Severity of spatial learning impairment in aging: development of a learning index for performance in the Morris water maze. Behav Neurosci 107: 618-626.
13. Gaskin S, Tremblay A, Mumby DG. 2003. Retrograde and anterograde object recognition in rats with hippocampal lesions. Hippocampus 13:962-969.
14. Green AR, Mechan AO, Elliott JM, O'Shea E, Colado MI. 2003. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy"). Pharmacol Rev 55:463-508.
15. Green AR, O'Shea EO, Colado MI. 2004. A review of the mechanisms involved in the acute MDMA (ecstasy)-induced hyperthermic response. Eur J Pharmacol 500:3-13.
16. Halpern JH, Pope HG Jr., Sherwood AR, Barry S, Hudson JI, Yurgelun-Todd D. 2004. Residual neuropsychological effects of illicit 3,4- methylenedioxymethamphetamine (MDMA) in individuals with minimal exposure to other drugs. Drug Alcohol Depend 75:135-147.
17. Harrison BJ, Olver JS, Norman TR, Burrows GD, Wesnes KA, Nathan PJ. 2004. Selective effects of acute serotonin and catecholamine depletion on memory in healthy women. J Psychopharmacol 18:32-40.
18. Henze DA, Gonzalez-Burgos GR, Urban NN, Lewis DA, Barrionuevo G. 2000. Dopamine increases excitability of pyramidal neurons in primate prefrontal cortex. J Neurophysiol 84:2799-2809.
19. Ho E, Karimi-Tabesh L, Koren G. 2001. Characteristics of pregnant women who use ecstasy (3,4-methylenedioxymethamphetamine). Neurotoxicol Teratol 23:561-567.
20. Holscher C. 1999. Stress impairs performance in spatial water maze learning tasks. Behav Brain Res 100:225-235.
21. Holson RR, Pearce B. 1992. Principles and pitfalls in the analysis of prenatal treatment effects in multiparous species. Neurotoxicol Teratol 14:221-228.
22. Horan B, Gardner EL, Ashby CR Jr. 2000. Enhancement of conditioned place preference response to cocaine in rats following subchronic administration of 3,4-methylenedioxymethamphetamine (MDMA). Synapse 35:160-162.
23. Koprich JB, Chen E-Y., Kanaan NM, Campbell NG, Kordower JH, Lipton JW. 2003. Prenatal 3,4-methylenedioxymethamphetamine (ecstasy) alters exploratory behavior, reduces monoamine metabolism, and increases forebrain tyrosine hydorxylase fiber density of juvenile rats. Neurotoxicol Teratol 25:509-517.
24. Laakso A, Wallius E, Kajander J, Bergman J, Eskola O, Solin O, Ilonen T, Salokangas RK, Syvalahti E, Hietala J. 2003. Personality traits and striatal dopamine synthesis capacity in healthy subjects. Am J Psychiatry 160:904-910.
25. Lieben CKJ, van Oorsouw K, Deutz NEP, Blokland A. 2004. Acute tryptophan depletion induced by a gelatin-based mixture impairs object memory but not affective behavior and spatial learning in the rat. Behav Brain Res 151:53-64.
26. Lindner MD. 1997. Reliability, distribution, and validity of age-related cognitive deficits in the Morris water maze. Neurobiol Learn Mem 68:203-220.
27. Littell RC, Milliken GA, Stroup WW, Wolfinger RD. 1996. Analysis of repeated measures data. In: SAS System for Mixed Models. Cary, NC: SAS Institute Inc. p 87-134.
28. Littell RC, Stroup WW, Freund RJ. 2002. Repeated-measures analysis. In: SAS for Linear Models, Fourth Edition. Gary, NC: SAS Institute Inc. p 265-303.
29. Marston HM, Reid ME, Lawrence JA, Olverman HJ, Butcher SP. 1999. Behavioural analysis of the acute and chronic effects of MDMA treatment in the rat. Psychopharmacology 144:67-76.
30. McCardle K, Luebbers S, Carter JD, Croft RJ, Stough C. 2004. Chronic MDMA (ecstasy) use, cognition and mood. Psychopharmacology 173:434-439.
31. McCreary AC, Bankson MG, Cunningham KA. 1999. Pharmacological studies of the acute and chronic effects of (+)-3,4-methylenedioxymethamphetamine on locomotor activity: role of 5-hydroxytryptamine 1A and 6-hydroxytryptamine 1b/1d receptors. J Pharmacol Exp Ther 290:965-973.
32. McElhatton PR, Bateman DN, Evans C, Pughe KR, Thomas SH. 1999. Congenital anomalies after prenatal ecstasy exposure. Lancet 354:1441-1442.
33. Meyer JS, Grande M, Johnson K, Ali SF. 2004. Neurotoxic effects of MDMA ("ecstasy") administration to neonatal rats. Int J Dev Neurosci 22:261-271.
34. Morford LL, Wheck JW, Breslin WJ, DeSesso JM. 2004. Hazard identification and predictability of children's health risk from animal data. Environ Health Perspect 112:266-271.
35. Morgan MJ. 1998. Recreational use of "ecstasy" (MDMA) is associated with elevated impulsivity. Neuropsychopharmacology 19:252-264.
36. Morgan MJ. 1999. Memory deficits associated with recreational use of "ecstasy" (MDMA). Psychopharmacology 141:30-36.
37. Morgan MJ. 2000. Ecstasy (MDMA): a review of its possible persistent psychological effects. Psychopharmacology 152:230-248.
38. Morgan MJ, McFie L, Fleetwood LH, Robinson JA. 2002. Ecstasy (MDMA): are the psychological problems associated with its use reversed by prolonged abstinence? Psychopharmacology 159:294-303.
39. Nair SG, Gudelsky GA. 2004. Protein kinase C inhibition differentially affects 3,4-methylenedioxymethamphetamine-induced dopamine release in the striatum and prefrontal cortex of the rat. Brain Res 1013:168-173.
40. Parrott AC. 2000. Human research on MDMA (3,4-methylene- dioxymethamphetamine) neurotoxicity: cognitive and behavioural indices of change. Neuropsychobiology 42:17-24.
41. Rodgers J. 2000. Cognitive performance amongst recreational users of "ecstasy". Psychopharmacology 151:19-24.
42. SAS Institute Inc. 1999. The CANCORR Procedure. In: SAS/STAT User's Guide, Version 8. Gary, NC: SAS Institute Inc. p 635-663.
43. Schwarting RK, Thiel CM, Muller CP, Huston JP. 1998. Relationship between anxiety and serotonin in the ventral striatum. Neuroreport 9:1025-1029.
44. Shepherd JK, Grewal SS, Fletcher A, Bill DJ, Dourish CT. 1994. Behavioural and pharmacological characterisation of the elevated "zero-maze" as an animal model of anxiety. Psychopharmacology 116:56-64.
45. Sprague JE, Preston AS, Leifheit M, Woodside B. 2003. Hippocampal serotonergic damage induced by MDMA (ecstasy): effects on spatial learning. Physiol Behav 79:281-287.
46. Turner JJ, Parrott AC. 2000. "Is MDMA a human neurotoxin?": diverse views from the discussants. Neuropsychobiology 42:42-48.
47. Verkes RJ, Gijsman HJ, Pieters MSM, Schoemaker RC, de Visser S, Kuijpers M, Pennings EJM, de Bruin D, van de Wijngaart G, van Gerven JMA, Cohen AF. 2001. Cognitive performance and serotonergic function in users of ecstasy. Psychopharmacology 153:196-202.
48. Vorhees CV 1987. Maze learning in rats: a comparison of performance in two water mazes in progeny prenatally exposed to different doses of pheytoin. Neurotoxicol Teratol 9:235-241.
49. Vorhees CV, Reed TM, Skelton MR, Williams MT. 2004. Exposure to 3,4-methylenedioxymethamphetamine (MDMA) on postnatal days 11-20 induces reference but not working memory deficits in the Morris water maze in rats: implications of prior learning. Int J Dev Neurosci 22:247-259.
50. Williams MT, Morford LL, McCrea AE, Wood SL, Vorhees CV 2002. Administration of D, L-fenfluramine to rats produces learning deficits in Cincinnati water maze but not the Morris water maze: relationship to adrenal cortical output. Neurotoxicol Teratol 24:783-796.
51. Williams MT, Moran MS, Vorhees CV 2003a. Refining the critical period for methampbetamine-induced spatial deficits in the Morris water maze. Psychopharmacology 168:329-338.
52. Williams MT, Morford LL, Wood SL, Rock SL, McCrea AE, Fukumura M, Wallace TL, Broening HW, Moran MS, Vorhees CV 2003b. Developmental 3,4- methylenedioxymethamphetamine (MDMA) impairs sequential and spatial but not cued learning independent of growth, litter effects or injection stress. Brain Res 968:89-101.